Chronic Obstructive Pulmonary DiseasePhase 3NCT00250679
Safety and Efficacy of Arformoterol Tartrate Inhalation Solution in Subjects With Chronic Obstructive Pulmonary Disease
A Phase 3 study testing Arformoterol tartrate inhalation solution, Arformoterol 25 ųg BID and Formoterol 12 ųg BID in people with Chronic Obstructive Pulmonary Disease and Bronchitis, run by Sumitomo Pharma America, Inc. at 60 sites in United States.
Trial summary
To evaluate the long-term safety and monitor the long-term efficacy of arformoterol over a period of 6 months in subjects with chronic obstructive pulmonary disease (COPD). Read more about this study
- Who is it for?
- Ages 35 years and older
- Conditions the study is for
- Chronic Obstructive Pulmonary Disease, Bronchitis, Emphysema
- What is being tested?
- Arformoterol tartrate inhalation solution, Arformoterol 25 ųg BID and Formoterol 12 ųg BID
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 443 participants
- Where
- 60 sitesUnited States
- Study dates
- Oct 2005to Oct 2007
- Phase
- Phase 3
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 35 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Male and female subjects must be at least 35 years old at the time of consent
- Subjects must have a pre-established, documented primary clinical diagnosis of non-asthmatic COPD or are referred for diagnosis of non-asthmatic COPD
- Subjects must have a >=15 pack-year smoking history and a baseline breathlessness severity grade of >=2 (Modified Medical Research Council [MMRC] Dyspnea Scale Score) at Visits 1 and 2
- Female subjects <=65 years of age must have a negative serum pregnancy test, females of childbearing potential must be using an acceptable method of birth control
- Subjects must be in general good health.
Who cannot join
- Subjects with a history of asthma, with the exception of asthma diagnosed in childhood
- Subjects with a blood eosinophil count >5% of total white blood cell count
- Subjects have had a febrile illness within 72 hours (3 days) before Screening Visit 1
- Subjects with a chest x-ray that suggests a diagnosis other than COPD (e.g., diagnostic of pneumonia, other infection, atelectasis, or pneumothorax or other active/ongoing pulmonary conditions)
Trial locations and contacts
60 sites in 1 country.
60 sites in 1 country
United States60 sites
Study site
Albuquerque, New Mexico
Study site
Ann Arbor, Michigan
Study site
Atlanta, Georgia, 30309
Study site
Baltimore, Maryland
Study site
Bay Pines, Florida, 33744
Study site
Birmingham, Alabama
Study site
Brandon, Florida
Study site
Carmichael, California
Study site
Chapel Hill, North Carolina
Study site
Charleston, South Carolina
Study site
Charlotte, North Carolina
Study site
Chester, Maryland
Study site
Cincinnati, Ohio
Study site
Columbia, South Carolina
Study site
Danville, Virginia
Study site
Denver, Colorado
Study site
East Providence, Rhode Island
Study site
East Slidell, Louisiana
Study site
Evansville, Indiana
Study site
Fullerton, California
Study site
Gainesville, Florida, 32605
Study site
Hartford, Connecticut
Study site
Houston, Texas
Study site
Jasper, Alabama
Study site
Katy, Texas
Study site
Knoxville, Tennessee
Study site
Lafayette, Louisiana
Study site
Lake Oswego, Oregon
Study site
Little Rock, Arkansas
Study site
Long Beach, California
Study site
Marietta, Georgia
Study site
Medford, Oregon, 97504
Study site
Metairie, Louisiana
Study site
Mobile, Alabama
Study site
Morgantown, West Virginia
Study site
Normal, Illinois
Study site
Panama City, Florida
Study site
Paramount, California
Study site
Pittsburgh, Pennsylvania
Study site
Rancho Mirage, California
Study site
Richmond, Virginia
Study site
Saint Charles, Missouri
Study site
San Antonio, Texas
Study site
San Diego, California
Study site
Simpsonville, South Carolina
Study site
Spartanburg, South Carolina
Study site
Spokane, Washington
Study site
St Louis, Missouri, 63117
Study site
St Louis, Missouri
Study site
Statesville, North Carolina, 28625
Study site
Sunset, Louisiana
Study site
Swarthmore, Pennsylvania
Study site
Tacoma, Washington
Study site
Tampa, Florida
Study site
Topeka, Kansas
Study site
Union, South Carolina, 29379
Study site
Walnut Creek, California
Study site
Wheaton, Maryland
Study site
Wilmington, North Carolina
Study site
Winston-Salem, North Carolina
About this study
Official title: Multicenter, Double-Blind, Double-Dummy, Randomized, Active-Controlled, Parallel Group Long-Term Safety Study of 15 μg and 25 μg Arformoterol Tartrate Inhalation Solution BID in Subjects With Chronic Obstructive Pulmonary Disease
To evaluate the long-term safety and monitor the long-term efficacy of arformoterol over a period of 6 months in subjects with chronic obstructive pulmonary disease (COPD).
Read the detailed description
This is a double-blind, double-dummy, multicenter, randomized, active-controlled, parallel group, outpatient, safety study to evaluate the long term safety of arformoterol in the treatment of subjects with COPD. Study participation will be over approximately 6 months. This study was previously posted by Sepracor Inc. In October 2009, Sepracor Inc. was acquired by Dainippon Sumitomo Pharma., and in October 2010, Sepracor Inc's name was changed to Sunovion Pharmaceuticals Inc.
- Conditions
- Chronic Obstructive Pulmonary Disease, Bronchitis, Emphysema
- Being tested
- Arformoterol tartrate inhalation solution, Arformoterol 25 ųg BID, Formoterol 12 ųg BID, Placebo
- Keywords
- COPD, chronic bronchitis, emphysema
- Medical subject headings
- Pulmonary Disease, Chronic Obstructive, Bronchitis, Emphysema, Bronchitis, Chronic
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Arformoterol tartrate inhalation solutionDrug
Also called Brovana®
Arformoterol 15 ųg BID by nebulization
Arformoterol 25 ųg BIDDrug
Also called Brovana, R,R formoterol
Arformoterol 25 ųg BID by nebulization
Formoterol 12 ųg BIDDrug
Also called Foradil, R,S-formoterol
Formoterol fumarate 12 ųg BID via aerolizer/DPI
PlaceboDrug
Placebo nebule or placebo aerolizer
| Study group | Role | What they receive |
|---|---|---|
| Formoterol 12 ųg 2x/day | Active comparator | Not described Receives: Drug: Formoterol 12 ųg BID; Drug: Placebo |
| Arformoterol 15 ųg 2x/day | Experimental | Not described Receives: Drug: Arformoterol tartrate inhalation solution; Drug: Placebo |
| Arformoterol 25 ųg 2x/day | Experimental | Not described Receives: Drug: Arformoterol 25 ųg BID; Drug: Placebo |
What is being measured
The primary outcome is the main question the study is designed to answer.
Percent (%) of Participants With Adverse Events (AEs), in Particular COPD Exacerbations
Percent of participants with the adverse event specified.
SOC = system organ class.
Measured: Six months
Secondary outcomes (30)
Number of Participants With New 24-Hour Holter Monitoring Alerts
New holter monitoring alerts are defined as those alerts that occurred post-randomization and were not present at baseline.
Measured: Visit 6 (week 27)
Number of Participants With Potentially Clinically Significant Glucose Evaluations
Patients with glucose values that met low (<=40 mg/dL) or high (>=175 mg/dL) criteria were considered potentially clinically significant.
Measured: visit 6 (week 27)
Number of Participants With Potentially Clinically Significant Potassium Evaluations
Patients with potassium values that met low (<=3 mEq/L) or high (>=6 mEq/L) criteria were considered potentially clinically significant.
Measured: visit 6 (week 27)
Number of Participants With New 12-Lead Electrocardiogram (ECG) Alerts
New Electrocardiogram (ECG) alerts are defined as those alerts that occurred post-treatment and were not present at baseline.
Measured: visit 6 (week 27)
Inspiratory Capacity Changes From Baseline
Mean Change in Inspiratory Capacity values from baseline (baseline assessment obtained at Visit 2, pre-dose). Spirometry measurements collected within 6 hours following in-clinic rescue/supplemental medications use were excluded from analysis.
Measured: weeks 0,3,13,26
6-Hour Peak Changes From Baseline in Forced Expiratory Volume (FEV1)
The 6 hour peak change from baseline is the maximum of the post-dose change values through 6 hours at each visit.
Measured: weeks 0,3,13,26
Number of Participants With Potentially Clinically Significant Heart Rate
Number of subjects with a heart rate that was lower/higher than a set limit and increased/decreased from set baseline limit in beats per minute (bpm)
Measured: visit 6 (week 27)
Ipratropium Bromide Metered Dose Inhaler (MDI) Usage: Days Used Per Week
Supplemental medication usage is recorded throughout the study. MDI stands for metered dose inhaler.
Measured: Screening (day-14 to 0) and Treatment (week 0 - 26)
Ipratropium Bromide Metered Dose Inhaler (MDI) Usage: Number of Actuations Per Day
Supplemental medication usage during the study. MDI stands for metered dose inhaler. An actuation is one depression of the device that releases medication.
Measured: Screening (day-14 to 0) and Treatment (week 0 - 26)
Racemic Albuterol or Levalbuterol Metered Dose Inhaler (MDI) Usage: Days Used Per Week
Rescue medication usage during the study. MDI stands for metered dose inhaler.
Measured: Screening (day-14 to 0) and Treatment (week 0 - 26)
Racemic Albuterol or Levalbuterol Metered Dose Inhaler (MDI) Usage: Number of Actuations Per Day
Rescue medication usage during the study. MDI stands for metered dose inhaler. An actuation is one depression of the device that releases medication.
Measured: Screening (day-14 to 0) and Treatment (week 0 - 26)
Time-Normalized Area Under the Curve (nAUC) From 0 to 6 Hrs for Forced Expiratory Volume in One Second (FEV1) Changes From Baseline
Area under the change from baseline curve from 0 to 6 hours. Time-normalized AUC (0-6 hrs) was derived using the linear trapezoidal method.
Measured: weeks 0,3,13,26
Transitional (Relative Change in) Dyspnea Index
The transitional focal score (-9 to 9) is the sum of relative change from baseline for the Functional Impairment, Magnitude of Task, and Magnitude of Effort scores (each -3 to 3 scale). A Transitional Dyspnea Index score of -9 represents a maximum degradation of all three tests; a score of 9 represents a maximum improvement of all three tests.
Measured: weeks 13, 26
Number of Participants With an Improved Transitional Dyspnea Index
The number of participants with a transitional focal score (range -9 to 9) of >=1 improvement. Transitional focal score compares current health against baseline for the Functional Impairment, Magnitude of Task, and Magnitude of Effort scores. A score of -9 is maximum worsening and 9 is maximum improvement.
Measured: weeks 13, 26
Forced Expiratory Volume in One Second (FEV1) Changes From Baseline for 24 Hour Post Dose Timepoint (Trough)
The 24 hour trough is the FEV1 value obtained 24 hours post first dose. This value is compared to the baseline FEV1 value.
Measured: weeks 0,3,13,26
Subject Global Evaluations Change From Baseline
The global evaluation is a COPD symptoms rating ranging from 1 to 7, with 1=much better and 7=much worse. Ratings were assessed relative to the subject's initial entry into the study.
Measured: weeks 13, 26
Investigator Global Evaluations Change From Baseline
The global evaluation is a COPD symptoms rating ranging from 1 to 7, with 1 = much better and 7 = much worse. Ratings were assessed relative to the subject's initial entry into the study.
Measured: weeks 13, 26
BODE Index
The BODE index (0=relative health and 10=severe chronic obstructive pulmonary disease) is a multi-dimension COPD grading system that incorporates body-mass index (B), degree of airflow obstruction (O), dyspnea (D), and exercise capacity (E) as measured by the 6-minute walk test. Scores were derived using pre-dose assessments from each visit.
Measured: Baseline (visit 2), weeks 13, 26
6-Minute Walk: Change From Baseline in the Distance Walked in 6 Minutes
Mean change from baseline in distance walked (meters)
Measured: Post-Dose weeks 0, 13, 26
Mean Change From Baseline in St. George's Respiratory Questionnaire
Scores are expressed as a mean change from baseline of overall impairment (total score). The questionnaire has a scale of 100 which represents worst possible health status to 0 which indicates best possible health status.
Measured: weeks 13, 26
Number of Participants With a >=4 Unit Improvement on the St. George's Respiratory Questionnaire
Scores are expressed as the number of participants with >= 4 unit improvement in overall impairment (total score), where 100 represents worst possible health status and 0 indicates best possible health status.
Measured: Visit 4 (week 13) , Visit 5 (week 26)
Modified Medical Research Council Dyspnea Questionaire
Scores range from 0 to 4, with a score of 4 indicating that a subject is too breathless to leave the house or becomes breathless when dressing or undressing. The highest numbered question to which the subject answered 'Yes' is the Dyspnea Scale Score.
Measured: Baseline (visit 2), weeks 13, 26
Percent (%) of Participants With an Improved Transitional Dyspnea Index
The percentage of participants with a transitional focal score (range -9 to 9) of >=1 improvement. Transitional focal score is the sum of the Functional Impairment, Magnitude of Task, and Magnitude of Effort scores. A score of -9 is maximum worsening and 9 is maximum improvement.
Measured: visits 4 (week 13), visit 5 (week 26)
Percent (%) of Participants With a >=4 Unit Improvement in the St. George's Respiratory Questionaire
Percent of participants with a >=4 unit improvement in the overall impairment (total score) of the St. George's Respiratory Questionaire. This questionaire uses a 100 - 0 scale, where 100 represents the worst possible health status and 0 indicates the best possible health status.
Measured: visit 4 (week 13), visit 5 (week 26)
Mean Values for the 6-Minute Walk Test: Distance Walked in Meters
This test measures the participants' level of fitness. It is a measure of the distance the participant can walk in 6 minutes.
Measured: Baseline (Visit 2), week 13, week 26
Mean Values for Investigator Global Evaluations
The investigator global evaluation is reported by the study investigator. It is a COPD symptoms rating ranging from 1 to 7, with 1 = much better and 7 = much worse.
Measured: Baseline (Visit 2), Weeks 13, 26
Mean Values for St. George's Respiratory Questionnaire
A questionnaire to assess respiratory health. Scores are expressed as a percentage of overall impairment (total score), where 100 represents the worst possible health status and 0 indicates best possible health status.
Measured: Baseline (Visit 2), weeks 13, 26
Mean Values for Subject Global Evaluations
The subject global evaluation is reported by study subjects/participants. It is a COPD symptoms rating ranging from 1 to 7, with 1 = much better and 7 = much worse.
Measured: Baseline (Visit 2), weeks 13, 26
Mean Values for Inspiratory Capacity
Inspiratory capacity is the maximum volume that can be inhaled.
Measured: Baseline (Visit 2), Weeks 3, 13, 26
Mean Values for Forced Expiratory Volume in One Second (FEV1)
Forced Expiratory Volume in one second
Measured: Baseline (Visit 2), weeks 3, 13, 26
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted8 Nov 2005 (estimated)
- Study startOct 2005
- Primary completionOct 2007
- Study completionOct 2007
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Chronic Obstructive Pulmonary DiseaseStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 3
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind
- Who is masked
- Participant, Care provider, Outcomes assessor
- Enrolment
- 443 participants (actual)
Sponsor and investigators
- Lead sponsor
- Sumitomo Pharma America, Inc.
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Sepracor Medical Director, Study director, Sumitomo Pharma America, Inc.
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT00250679
- Sponsor's protocol ID
- 091-061
- Status last verified
- May 2012
- First submitted
- 4 Nov 2005
- Last updated
- 4 Jun 2012
- Results posted
- Yes, on ClinicalTrials.gov
- Data monitoring committee
- Yes
Publications
Hanania NA, Donohue JF, Nelson H, Sciarappa K, Goodwin E, Baumgartner RA, Hanrahan JP. The safety and efficacy of arformoterol and formoterol in COPD. COPD. 2010 Feb;7(1):17-31. doi: 10.3109/15412550903499498.
PubMed 20214460
Study at a glance
From the registry record, last updated by the sponsor on 4 Jun 2012. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Multicenter, Double-Blind, Double-Dummy, Randomized, Active-Controlled, Parallel Group Long-Term Safety Study of 15 μg and 25 μg Arformoterol Tartrate Inhalation Solution BID in Subjects With Chronic Obstructive Pulmonary Disease
- ClinicalTrials.gov ID
- NCT00250679
- Acronym / sponsor ID
- 091-061
- Conditions
- Chronic Obstructive Pulmonary Disease, Bronchitis, Emphysema
- Keywords
- COPD, chronic bronchitis, emphysema
- Phase
- Phase 3
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 443 participants (actual)
- Lead sponsor
- Sumitomo Pharma America, Inc.Industry (pharma, biotech, devices)
- Study start
- Oct 2005
- Primary completion
- Oct 2007 (actual)
- Study completion
- Oct 2007 (actual)
- First posted
- 8 Nov 2005 (estimated)
- Results
- Posted 19 Feb 2009
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
To evaluate the long-term safety and monitor the long-term efficacy of arformoterol over a period of 6 months in subjects with chronic obstructive pulmonary disease (COPD).
Detailed description
This is a double-blind, double-dummy, multicenter, randomized, active-controlled, parallel group, outpatient, safety study to evaluate the long term safety of arformoterol in the treatment of subjects with COPD. Study participation will be over approximately 6 months. This study was previously posted by Sepracor Inc. In October 2009, Sepracor Inc. was acquired by Dainippon Sumitomo Pharma., and in October 2010, Sepracor Inc's name was changed to Sunovion Pharmaceuticals Inc.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind (participant, care provider, outcomes assessor)
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| Formoterol 12 ųg 2x/day | Active comparator | Drug: Formoterol 12 ųg BID, Drug: Placebo |
| Arformoterol 15 ųg 2x/day | Experimental | Drug: Arformoterol tartrate inhalation solution, Drug: Placebo |
| Arformoterol 25 ųg 2x/day | Experimental | Drug: Arformoterol 25 ųg BID, Drug: Placebo |
Who may qualify
- Ages
- 35 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (5 listed)
- Male and female subjects must be at least 35 years old at the time of consent
- Subjects must have a pre-established, documented primary clinical diagnosis of non-asthmatic COPD or are referred for diagnosis of non-asthmatic COPD
- Subjects must have a >=15 pack-year smoking history and a baseline breathlessness severity grade of >=2 (Modified Medical Research Council [MMRC] Dyspnea Scale Score) at Visits 1 and 2
- Female subjects <=65 years of age must have a negative serum pregnancy test, females of childbearing potential must be using an acceptable method of birth control
- Subjects must be in general good health.
Key exclusion criteria (4 listed)
- Subjects with a history of asthma, with the exception of asthma diagnosed in childhood
- Subjects with a blood eosinophil count >5% of total white blood cell count
- Subjects have had a febrile illness within 72 hours (3 days) before Screening Visit 1
- Subjects with a chest x-ray that suggests a diagnosis other than COPD (e.g., diagnostic of pneumonia, other infection, atelectasis, or pneumothorax or other active/ongoing pulmonary conditions)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Arformoterol tartrate inhalation solutionAlso: Brovana®Arformoterol 15 ųg BID by nebulization | Drug | Arformoterol 15 ųg 2x/day |
| Arformoterol 25 ųg BIDAlso: Brovana, R,R formoterolArformoterol 25 ųg BID by nebulization | Drug | Arformoterol 25 ųg 2x/day |
| Formoterol 12 ųg BIDAlso: Foradil, R,S-formoterolFormoterol fumarate 12 ųg BID via aerolizer/DPI | Drug | Formoterol 12 ųg 2x/day |
| PlaceboPlacebo nebule or placebo aerolizer | Drug | Arformoterol 15 ųg 2x/day, Arformoterol 25 ųg 2x/day, Formoterol 12 ųg 2x/day |
Primary outcome
Percent (%) of Participants With Adverse Events (AEs), in Particular COPD Exacerbations
Time frame: Six months
Percent of participants with the adverse event specified. SOC = system organ class.
30 secondary outcomes
Number of Participants With New 24-Hour Holter Monitoring Alerts
Time frame: Visit 6 (week 27)
Number of Participants With Potentially Clinically Significant Glucose Evaluations
Time frame: visit 6 (week 27)
Number of Participants With Potentially Clinically Significant Potassium Evaluations
Time frame: visit 6 (week 27)
Number of Participants With New 12-Lead Electrocardiogram (ECG) Alerts
Time frame: visit 6 (week 27)
Inspiratory Capacity Changes From Baseline
Time frame: weeks 0,3,13,26
6-Hour Peak Changes From Baseline in Forced Expiratory Volume (FEV1)
Time frame: weeks 0,3,13,26
Number of Participants With Potentially Clinically Significant Heart Rate
Time frame: visit 6 (week 27)
Ipratropium Bromide Metered Dose Inhaler (MDI) Usage: Days Used Per Week
Time frame: Screening (day-14 to 0) and Treatment (week 0 - 26)
Ipratropium Bromide Metered Dose Inhaler (MDI) Usage: Number of Actuations Per Day
Time frame: Screening (day-14 to 0) and Treatment (week 0 - 26)
Racemic Albuterol or Levalbuterol Metered Dose Inhaler (MDI) Usage: Days Used Per Week
Time frame: Screening (day-14 to 0) and Treatment (week 0 - 26)
Racemic Albuterol or Levalbuterol Metered Dose Inhaler (MDI) Usage: Number of Actuations Per Day
Time frame: Screening (day-14 to 0) and Treatment (week 0 - 26)
Time-Normalized Area Under the Curve (nAUC) From 0 to 6 Hrs for Forced Expiratory Volume in One Second (FEV1) Changes From Baseline
Time frame: weeks 0,3,13,26
Transitional (Relative Change in) Dyspnea Index
Time frame: weeks 13, 26
Number of Participants With an Improved Transitional Dyspnea Index
Time frame: weeks 13, 26
Forced Expiratory Volume in One Second (FEV1) Changes From Baseline for 24 Hour Post Dose Timepoint (Trough)
Time frame: weeks 0,3,13,26
Subject Global Evaluations Change From Baseline
Time frame: weeks 13, 26
Investigator Global Evaluations Change From Baseline
Time frame: weeks 13, 26
BODE Index
Time frame: Baseline (visit 2), weeks 13, 26
6-Minute Walk: Change From Baseline in the Distance Walked in 6 Minutes
Time frame: Post-Dose weeks 0, 13, 26
Mean Change From Baseline in St. George's Respiratory Questionnaire
Time frame: weeks 13, 26
Number of Participants With a >=4 Unit Improvement on the St. George's Respiratory Questionnaire
Time frame: Visit 4 (week 13) , Visit 5 (week 26)
Modified Medical Research Council Dyspnea Questionaire
Time frame: Baseline (visit 2), weeks 13, 26
Percent (%) of Participants With an Improved Transitional Dyspnea Index
Time frame: visits 4 (week 13), visit 5 (week 26)
Percent (%) of Participants With a >=4 Unit Improvement in the St. George's Respiratory Questionaire
Time frame: visit 4 (week 13), visit 5 (week 26)
Mean Values for the 6-Minute Walk Test: Distance Walked in Meters
Time frame: Baseline (Visit 2), week 13, week 26
Mean Values for Investigator Global Evaluations
Time frame: Baseline (Visit 2), Weeks 13, 26
Mean Values for St. George's Respiratory Questionnaire
Time frame: Baseline (Visit 2), weeks 13, 26
Mean Values for Subject Global Evaluations
Time frame: Baseline (Visit 2), weeks 13, 26
Mean Values for Inspiratory Capacity
Time frame: Baseline (Visit 2), Weeks 3, 13, 26
Mean Values for Forced Expiratory Volume in One Second (FEV1)
Time frame: Baseline (Visit 2), weeks 3, 13, 26
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 4 Jun 2012.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
- Background: PubMed 20214460Hanania NA, Donohue JF, Nelson H, Sciarappa K, Goodwin E, Baumgartner RA, Hanrahan JP. The safety and efficacy of arformoterol and formoterol in COPD. COPD. 2010 Feb;7(1):17-31. doi: 10.3109/15412550903499498.
Related trials for Chronic Obstructive Pulmonary Disease
Active, not recruiting
Symptoms and Functions in Patients With COPD and Chronic Bronchitis Switching From CIG to THS
COPD, Smoking
Not yet recruitingPhase 2/3
An Open-Label Extension Study to Evaluate Inhaled Treprostinil SMI in Participants With Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease (PH-COPD)
Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease
Not yet recruiting
The Aim of the Study is to Decipher the Alterations in Signalling Pathways of Skeletal Muscle Stem Cells (Satellite Cells (SCs)) in Individuals With COPD, as Well as to Examine the Effect of Exercise Training on SCs.
COPD (Chronic Obstructive Pulmonary Disease), Sarcopenia in Elderly
Not yet recruitingPhase 2
Study of Treprostinil Administered Via Soft Mist Inhaler (SMI) in Participants With Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease (PH-COPD)
Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease
RecruitingPhase 3
A Study to Investigate the Efficacy and Safety of Belumosudil Compared With Best Available Therapy in Participants Aged 12 Years or Older With Chronic Graft-versus-host Disease
Chronic Graft Versus Host Disease
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Sepracor Medical Director study director
Sumitomo Pharma America, Inc.
60 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 3 study testing Arformoterol tartrate inhalation solution, Arformoterol 25 ųg BID and Formoterol 12 ųg BID in people with Chronic Obstructive Pulmonary Disease and Bronchitis, run by Sumitomo Pharma America, Inc. at 60 sites in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 4 Jun 2012. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 60 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
Yes. Results are posted in the registry (first posted 19 Feb 2009). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Percent (%) of Participants With Adverse Events (AEs), in Particular COPD Exacerbations (time frame: Six months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT00250679, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 4 Jun 2012.